BIDMC researchers develop decision-making tool to benefit patients with HCV
An estimated 3.5 million people in the United States have chronic hepatitis C (HCV), according to the Centers for Disease Control and Prevention. It is the most common cause for cirrhosis and liver cancer in the United States and the leading indication for liver transplantation. While recently developed direct anti-viral agents (DAAs) have proven to be a highly effective treatment option for many patients with HCV, those with decompensated HCV cirrhosis or liver failure may experience little to no improvement in liver function following eradication of HCV.
Published in the June, 2018, issue of Gastroenterology, BIDMC researchers led a retrospective analysis of four randomized clinical trials focused on the effects of DAA therapies in patients with HCV-associated liver failure, and developed a new means of predicting improvement in liver function in response to DAA treatment. The online scoring system, called the BE3A score, assesses 5 baseline factors (body mass index, encephalopathy, ascites and serum levels of alanine aminotransferase and albumin) to provide physicians with a shared decision-making tool to quantify the potential benefits of DAA therapy for patients with decompensated cirrhosis.
"Doctors and patients need to decide when a patient should receive HCV treatment in the setting of decompensated cirrhosis from HCV and whether to treat before, or defer treatment until after liver transplant," wrote study authors Michael P. Curry, MD, Section Chief of Hepatology at BIDMC and Z. Gordon Jiang, MD, a translational investigator at BIDMC's Liver Center. "Our study combined all of the data from smaller studies, allowing us to have a large enough sample size to determine predictors of improvement in liver function. With this analysis, we created a tool for shared decision-making for doctors and patients in this exact clinical scenario. "
In addition to Curry and Jiang, authors of the study include Omar El-Sherif of St James's Hospital, Elliot B. Tapper of the University of Michigan, K.C. Huang of Gilead Sciences, Alex Zhong of BIDMC, Anu Osinusi of Gilead Sciences, Michael Charlton of the University of Chicago, Michael Manns of the University of California San Francisco, Nezam H. Afdhal of BIDMC, Kenneth Mukamal of BIDMC, John McHutchison of Gilead Sciences, Diana M. Brainard of Gilead Sciences, and Norah Terrault of Hannover Medical School.
This work was supported by Gilead Sciences, BMS, the Health Research Board of Ireland, the American College of Gastroenterology, the American Association for the Study of Liver Diseases, AbbVie, Merck, Roche, Gilead, Novartis, Janssen and GlaxoSmithKline.